The has ruled that pharmaceutical regulatory authorities cannot concurrently suspend a drug license while issuing a (SCN). In an order delivered by the Hon’ble Mr. Justice C.M. Poonacha, the court clarified that the require a licensee to be granted an effective opportunity to explain their position before any or cancellation is enacted. This decision provides significant relief to , whose operations were initially disrupted by a issued on .
The dispute arose after the issued a combined notice alleging that the petitioner had procured specific pharmaceutical products through unauthorized channels. Specifically, the authorities claimed that the pharmacy chain had sourced "Zavicefta Injection" from , an entity allegedly not part of the authorized supply chain established by , the manufacturer. Based on these allegations, the licensing authority suspended the pharmacy’s license immediately, effectively halting its business operations across the affected locations.
In its challenge, the petitioner argued that the summary action was arbitrary, illegal, and conducted in violation of the procedures mandated by the , and the associated rules. The legal team contended that such a drastic step, which cripples the commercial operations of a business entity, cannot be taken without first allowing the licensee to present their defense against the specific charges.
Judicial Clarification on Rule 66 The court examined the scope of , which governs the cancellation and suspension of licenses. Justice Poonacha emphasized that the rule clearly contemplates a two-stage process: first, the issuance of a notice providing the licensee an opportunity to show cause, and second, an order issued in writing stating the reasons for the action, provided the licensee fails to satisfy the authority.
Refuting the current practices where show cause notices are often bundled with immediate suspension orders, the court stated, “A plain reading of sub-Rule (1) of Rule 66 of the Rules clearly indicates that the petitioner is entitled to be given a before an order of either suspension or cancellation is passed.”
The court held that by suspending the license at the same time it issued the notice, the respondent authorities had bypassed the fundamental requirement of natural justice. Consequently, the High Court directed that the dated , be treated strictly as a . This transition allows the pharmacy chain to formally address the allegations leveled against them rather than forcing them to operate under the shadow of an existing suspension.
Operational Relief and Ongoing Investigation As part of the granted to the petitioner, the court permitted the pharmacy to resume its pharmaceutical distribution and retail business. However, this permission comes with specific constraints to ensure that the ongoing regulatory inquiry is not compromised. The petitioner is authorized to operate in accordance with the law, with the express exception of dealing with the two specific products central to the dispute: "Zavicefta" and "Emblaveo" injections.
This interim measure ensures that while the pharmacy maintains its operational viability, it remains strictly prohibited from distributing the specific batches or types of medications under investigation by the state authorities. The petitioner has been directed to provide an additional response to the by . Following this submission, the licensing authority is mandated to pass a in compliance with the provisions of the Act.
The court’s directive serves as a reminder to state regulatory bodies regarding the importance of procedural rigor. By emphasizing that authorities must not conflate the allegation stage with the penalization stage, the High Court has reinforced the protection of commercial interests against potentially premature administrative actions. Addressing the nature of the impugned order, Justice Poonacha remarked, “In the present case, vide the cum order, the Petitioner has not only been notified of the allegation/assertion against it, but the license of the petitioner has also been suspended, which is contrary to sub-Rule (1) of Rule 66.”
Procedural Next Steps The regulatory authorities are now tasked with reviewing the comprehensive reply submitted by the petitioner. The court has explicitly noted that its intervention does not preclude the authorities from taking future legal measures, provided those actions strictly adhere to the legislative framework. The order states that the authorities must evaluate the failure or contravention alleged while considering the licensee’s specific justifications, as permitted under the , which looks into whether such acts were instigated or connived by the licensee or if they occurred despite the application of due diligence.
The case underscores the delicate balance between the state's duty to monitor pharmaceutical distribution channels—critical for patient safety and the integrity of the supply chain—and the need to protect businesses from abrupt administrative closures. As the matter proceeds toward a final administrative determination, the pharmacy is expected to cooperate fully with the , providing necessary documentation to clarify how the products in question were acquired.
The immediate consequence of the High Court’s ruling is that the pharmacy chain may continue its operations, preventing potential losses and the disruption of medicine availability to its customers, while the regulatory process continues under the bounds of legal propriety. The authorities are now under strict timelines to finalize their inquiry, ensuring that the pharmacy’s license status is settled in a manner that is both fair and compliant with the stringent requirements of the 1945 Rules. The case remains open for further regulatory assessment based on the upcoming submissions, ensuring that the final outcome will be based on a thorough and fair evaluation of the facts rather than an initial, summary determination.
licensing authority - natural justice
